


Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	209	jackowski-g\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:12
L2	92	thatcher-b\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:12
L3	1774	marshall-j\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:12
L4	78	yantha-j\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:12
L5	78	vrees-t\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:20
L6	1861	L1 OR L2 OR L3 OR L4 OR L5 AND ((cardiovascular ADJ disease) OR (myocardial ADJ infarction))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:14
L7	1861	L1 OR L2 OR L3 OR L4 OR L5 AND ((cardiovascular ADJ disease) OR (myocardial ADJ infarction)).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:15
L8	11960	((cardiovascular ADJ disease)OR(myocardial ADJ infarction)).ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:14
L9	1861	L1 OR L2 OR L3 OR L4 OR L5 AND ((cardiovascular ADJ disease) OR (myocardial ADJ infarction)).ab. AND marker.ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:15
L10	2	WO-9614580-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:45

L11	10	"5827659"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:44
L12	7	"5817768"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:44
L13	95	"5538897"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:44
L14	0	WO-0009562-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:45
L15	1	WO-200009562-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:45
L16	1	WO-200105422-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:45
L17	1	WO-200049410-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:46
L18	1	WO-200175454-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:46
L19	0	WO-199807036-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:46
L20	2	WO-9807036-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:46

L21	2	WO-9014148-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:47
L22	2	WO-9324834-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:47
L23	90	"6020208"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:47
L24	88	"5062935"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 11:49
L25	1720	530/300,326,350.ccls. AND (myocardial ADJ infarction)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 12:08
L26	2	wo-9636986-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 12:12
L27	2	wo-9942119-\$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/01/21 12:12



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bo

Search PubMed for

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

- Enter terms and click Preview to see only the number of search results.
- To combine searches use # before search number, e.g., (#2 OR #3) AND asthma.
- Click on query # to add to strategy

Search	Most Recent Queries	Time	Result
#17	Related Articles for PubMed (Select 14989564)	11:53:28	549
#16	Search fibrinogen AND myocardial infarction AND (marker OR biomarker)	11:53:18	295
#15	Search myocardial infarction AND (marker OR biomarker)	11:52:49	4324

Add Term(s) to Query or View Index:

- Enter a term in the text box; use the pull-down menu to specify a search field.
- Click Preview to add terms to the query box and see the number of search results, or click Index to view terms within a field.

All Fields

Click to add a term to the query box.

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jan 12 2005 06:52:28

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653aud

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and
February 2005
NEWS 17 JAN 11 CA/CAPLUS - Expanded patent coverage to include Russia
(Federal Institute of Industrial Property)

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:22:08 ON 21 JAN 2005

=> file registry		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:22:30 ON 21 JAN 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

-----Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2005 HIGHEST RN 817158-90-0
 DICTIONARY FILE UPDATES: 19 JAN 2005 HIGHEST RN 817158-90-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s fibrinogen
 1024 FIBRINOGEN
 6 FIBRINOGENS
 L1 1029 FIBRINOGEN
 (FIBRINOGEN OR FIBRINOGENS)

=> index bioscience medicine
 FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
 COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.03	5.24

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
 AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
 BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
 CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 12:23:04 ON 21 JAN 2005

78 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
 search error messages that display as 0* with SET DETAIL OFF.

=> s fibrinogen
 2029 FILE ADISCTI
 138 FILE ADISINSIGHT
 268 FILE ADISNEWS
 502 FILE AGRICOLA
 161 FILE ANABSTR
 57 FILE ANTE
 4 FILE AQUALINE
 105 FILE AQUASCI
 450 FILE BIOBUSINESS
 118 FILE BIOCOMMERCE
 515 FILE BIOENG

31334	FILE BIOSIS
576	FILE BIOTECHABS
576	FILE BIOTECHDS
6481	FILE BIOTECHNO
2010	FILE CABA
3587	FILE CANCERLIT
30223	FILE CAPLUS
115	FILE CEABA-VTB
5	FILE CEN
92	FILE CIN
695	FILE CONFSCI
11	FILE CROPU
1921	FILE DDFB
5797	FILE DDFU
5877	FILE DGENE
719	FILE DISSABS
1921	FILE DRUGB
99	FILE DRUGMONOG2
8235	FILE DRUGU
194	FILE EMBAL
34408	FILE EMBASE
5465	FILE ESBIODBASE
305	FILE FEDRIP
164	FILE FROSTI
38 FILES SEARCHED...	
134	FILE FSTA
4405	FILE GENBANK
44	FILE HEALSAFE
2002	FILE IFIPAT
48	FILE IMSDRUGNEWS
58	FILE IMSPRODUCT
61	FILE IMSRESEARCH
3834	FILE JICST-EPLUS
3	FILE KOSMET
2542	FILE LIFESCI
17	FILE MEDICONF
37491	FILE MEDLINE
164	FILE NIOSHTIC
354	FILE NTIS
4	FILE NUTRACEUT
15	FILE OCEAN
9706	FILE PASCAL
281	FILE PHAR
41	FILE PHARMAML
1	FILE PHIC
279	FILE PHIN
677	FILE PROMT
1752	FILE PROUSDDR
1	FILE PS
2	FILE RDISCLOSURE
64 FILES SEARCHED...	
22169	FILE SCISEARCH
17	FILE SYNTHLINE
12419	FILE TOXCENTER
11170	FILE USPATFULL
755	FILE USPAT2
27	FILE VETB
174	FILE VETU
3	FILE WATER
2425	FILE WPIDS
18	FILE WPIFV
2425	FILE WPINDEX
408	FILE IPA

86 FILE NAPRALERT
573 FILE NLDB

74 FILES HAVE ONE OR MORE ANSWERS, 78 FILES SEARCHED IN STNINDEX

L2 QUE FIBRINOGEN

=> d rank

F1	37491	MEDLINE
F2	34408	EMBASE
F3	31334	BIOSIS
F4	30223	CAPLUS
F5	22169	SCISEARCH
F6	12419	TOXCENTER
F7	11170	USPATFULL
F8	9706	PASCAL
F9	8235	DRUGU
F10	6481	BIOTECHNO
F11	5877	DGENE
F12	5797	DDFU
F13	5465	ESBIOBASE
F14	4405	GENBANK
F15	3834	JICST-EPLUS
F16	3587	CANCERLIT
F17	2542	LIFESCI
F18	2425	WPIDS
F19	2425	WPINDEX
F20	2029	ADISCTI
F21	2010	CABA
F22	2002	IFIPAT
F23	1921	DDFB
F24	1921	DRUGB
F25	1752	PROUSDDR
F26	755	USPAT2
F27	719	DISSABS
F28	695	CONFSCI
F29	677	PROMT
F30	576	BIOTECHABS
F31	576	BIOTECHDS
F32	573	NLDB
F33	515	BIOENG
F34	502	AGRICOLA
F35	450	BIOBUSINESS
F36	408	IPA
F37	354	NTIS
F38	305	FEDRIP
F39	281	PHAR
F40	279	PHIN
F41	268	ADISNEWS
F42	194	EMBAL
F43	174	VETU
F44	164	FROSTI
F45	164	NIOSHTIC
F46	161	ANABSTR
F47	138	ADISINSIGHT
F48	134	FSTA
F49	118	BIOCOMMERCE
F50	115	CEABA-VTB
F51	105	AQUASCI
F52	99	DRUGMONOG2
F53	92	CIN
F54	86	NAPRALERT
F55	61	IMSRESEARCH

F56	58	IMSPRODUCT
F57	57	ANTE
F58	48	IMSDRUGNEWS
F59	44	HEALSAFE
F60	41	PHARMAML
F61	27	VETB
F62	18	WPIFV
F63	17	MEDICONF
F64	17	SYNTHLINE
F65	15	OCEAN
F66	11	CROPU
F67	5	CEN
F68	4	AQUALINE
F69	4	NUTRACEUT
F70	3	KOSMET
F71	3	WATER
F72	2	RDISCLOSURE
F73	1	PHIC
F74	1	PS

=> file f1, f2, f3, f4, f5, f6, f7, f8, f9, f10
 COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.95	8.19

FILE 'MEDLINE' ENTERED AT 12:25:57 ON 21 JAN 2005

FILE 'EMBASE' ENTERED AT 12:25:57 ON 21 JAN 2005
 COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:25:57 ON 21 JAN 2005
 Copyright (c) 2005 The Thomson Corporation.

FILE 'CAPLUS' ENTERED AT 12:25:57 ON 21 JAN 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 12:25:57 ON 21 JAN 2005
 Copyright (c) 2005 The Thomson Corporation.

FILE 'TOXCENTER' ENTERED AT 12:25:57 ON 21 JAN 2005
 COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 12:25:57 ON 21 JAN 2005
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PASCAL' ENTERED AT 12:25:57 ON 21 JAN 2005
 Any reproduction or dissemination in part or in full,
 by means of any process and on any support whatsoever
 is prohibited without the prior written agreement of INIST-CNRS.
 COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'DRUGU' ENTERED AT 12:25:57 ON 21 JAN 2005
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 12:25:57 ON 21 JAN 2005
 COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s fibrinogen
 L3 203636 FIBRINOGEN

```
=> s myocardial infarction
L4      473386 MYOCARDIAL INFARCTION

=> s myocardial (w) infarction
L5      473386 MYOCARDIAL (W) INFARCTION

=> s (marker OR (biomarker)) AND L3 AND L5
L6      2525 (MARKER OR (BIOMARKER)) AND L3 AND L5
```

```
=> dup rem l6
PROCESSING IS APPROXIMATELY 49% COMPLETE FOR L6
PROCESSING IS APPROXIMATELY 86% COMPLETE FOR L6
PROCESSING COMPLETED FOR L6
L7      1897 DUP REM L6 (628 DUPLICATES REMOVED)
```

```
=> s jackowski,g?/au
L8      670 JACKOWSKI,G?/AU
```

```
=> s thatcher,b?/au
L9      237 THATCHER,B?/AU
```

```
=> s marshall,j?/au
L10     19338 MARSHALL,J?/AU
```

```
=> s yantha,j?/au
L11     90 YANTHA,J?/AU
```

```
=> s vrees,t?/au
L12     87 VREES,T?/AU
```

```
=> s L8 OR L9 OR L10 OR L11 OR L12
L13     19980 L8 OR L9 OR L10 OR L11 OR L12
```

```
=> dup rem l13
PROCESSING IS APPROXIMATELY 6% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 12% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 21% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 27% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 34% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 41% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 46% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 54% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 60% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 71% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 76% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 83% COMPLETE FOR L13
PROCESSING IS APPROXIMATELY 95% COMPLETE FOR L13
PROCESSING COMPLETED FOR L13
L14     9671 DUP REM L13 (10309 DUPLICATES REMOVED)
```

```
=> d his
```

(FILE 'HOME' ENTERED AT 12:22:08 ON 21 JAN 2005)

```
FILE 'REGISTRY' ENTERED AT 12:22:30 ON 21 JAN 2005
L1      1029 S FIBRINOGEN
```

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 12:23:04 ON 21 JAN 2005
SEA FIBRINOGEN

2029	FILE ADISCTI
138	FILE ADISINSIGHT
268	FILE ADISNEWS
502	FILE AGRICOLA
161	FILE ANABSTR
57	FILE ANTE
4	FILE AQUALINE
105	FILE AQUASCI
450	FILE BIOBUSINESS
118	FILE BIOCOMMERCE
515	FILE BIOENG
31334	FILE BIOSIS
576	FILE BIOTECHABS
576	FILE BIOTECHDS
6481	FILE BIOTECHNO
2010	FILE CABA
3587	FILE CANCERLIT
30223	FILE CAPLUS
115	FILE CEABA-VTB
5	FILE CEN
92	FILE CIN
695	FILE CONFSCI
11	FILE CROPU
1921	FILE DDFB
5797	FILE DDFU
5877	FILE DGENE
719	FILE DISSABS
1921	FILE DRUGB
99	FILE DRUGMONOG2
8235	FILE DRUGU
194	FILE EMBAL
34408	FILE EMBASE
5465	FILE ESBIODBASE
305	FILE FEDRIP
164	FILE FROSTI
134	FILE FSTA
4405	FILE GENBANK
44	FILE HEALSAFE
2002	FILE IFIPAT
48	FILE IMSDRUGNEWS
58	FILE IMSPRODUCT
61	FILE IMSRESEARCH
3834	FILE JICST-EPLUS
3	FILE KOSMET
2542	FILE LIFESCI
17	FILE MEDICONF
37491	FILE MEDLINE
164	FILE NIOSHTIC
354	FILE NTIS
4	FILE NUTRACEUT
15	FILE OCEAN
9706	FILE PASCAL
281	FILE PHAR
41	FILE PHARMAML
1	FILE PHIC
279	FILE PHIN
677	FILE PROMT
1752	FILE PROUSDDR
1	FILE PS
2	FILE RDISCLOSURE
22169	FILE SCISEARCH
17	FILE SYNTHLINE
12419	FILE TOXCENTER

11170 FILE USPATFULL
 755 FILE USPAT2
 27 FILE VETB
 174 FILE VETU
 3 FILE WATER
 2425 FILE WPIDS
 18 FILE WPIFV
 2425 FILE WPINDEX
 408 FILE IPA
 86 FILE NAPRALERT
 573 FILE NLDB

L2----- QUE FIBRINOGEN -----

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, SCISEARCH, TOXCENTER, USPATFULL, PASCAL, DRUGU, BIOTECHNO' ENTERED AT 12:25:57 ON 21 JAN 2005

L3 203636 S FIBRINOGEN
 L4 473386 S MYOCARDIAL INFARCTION
 L5 473386 S MYOCARDIAL (W) INFARCTION
 L6 2525 S (MARKER OR (BIOMARKER)) AND L3 AND L5
 L7 1897 DUP REM L6 (628 DUPLICATES REMOVED)
 L8 670 S JACKOWSKI,G?/AU
 L9 237 S THATCHER,B?/AU
 L10 19338 S MARSHALL,J?/AU
 L11 90 S YANTHA,J?/AU
 L12 87 S VREES,T?/AU
 L13 19980 S L8 OR L9 OR L10 OR L11 OR L12
 L14 9671 DUP REM L13 (10309 DUPLICATES REMOVED)

=> s L7 NOT L14
 7 FILES SEARCHED...
 L15 1889 L7 NOT L14

=> s L7 AND L14
 7 FILES SEARCHED...
 L16 8 L7 AND L14

=> d his

(FILE 'HOME' ENTERED AT 12:22:08 ON 21 JAN 2005)

FILE 'REGISTRY' ENTERED AT 12:22:30 ON 21 JAN 2005
 L1 1029 S FIBRINOGEN

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 12:23:04 ON 21 JAN 2005
 SEA FIBRINOGEN

2029 FILE ADISCTI
 138 FILE ADISINSIGHT
 268 FILE ADISNEWS
 502 FILE AGRICOLA
 161 FILE ANABSTR
 57 FILE ANTE
 4 FILE AQUALINE
 105 FILE AQUASCI
 450 FILE BIOBUSINESS
 118 FILE BIOCOMMERCE
 515 FILE BIOENG
 31334 FILE BIOSIS
 576 FILE BIOTECHABS

576	FILE BIOTECHDS
6481	FILE BIOTECHNO
2010	FILE CABA
3587	FILE CANCERLIT
30223	FILE CAPLUS
115	FILE CEABA-VTB
5	FILE CEN
92	FILE CIN
695	FILE CONFSCI
11	FILE CROPU
1921	FILE DDFB
5797	FILE DDFU
5877	FILE DGENE
719	FILE DISSABS
1921	FILE DRUGB
99	FILE DRUGMONOG2
8235	FILE DRUGU
194	FILE EMBAL
34408	FILE EMBASE
5465	FILE ESBIODBASE
305	FILE FEDRIP
164	FILE FROSTI
134	FILE FSTA
4405	FILE GENBANK
44	FILE HEALSAFE
2002	FILE IFIPAT
48	FILE IMSDRUGNEWS
58	FILE IMSPRODUCT
61	FILE IMSRESEARCH
3834	FILE JICST-EPLUS
3	FILE KOSMET
2542	FILE LIFESCI
17	FILE MEDICONF
37491	FILE MEDLINE
164	FILE NIOSHTIC
354	FILE NTIS
4	FILE NUTRACEUT
15	FILE OCEAN
9706	FILE PASCAL
281	FILE PHAR
41	FILE PHARMAML
1	FILE PHIC
279	FILE PHIN
677	FILE PROMT
1752	FILE PROUSDDR
1	FILE PS
2	FILE RDISCLOSURE
22169	FILE SCISEARCH
17	FILE SYNTHLINE
12419	FILE TOXCENTER
11170	FILE USPATFULL
755	FILE USPAT2
27	FILE VETB
174	FILE VETU
3	FILE WATER
2425	FILE WPIDS
18	FILE WPIFV
2425	FILE WPINDEX
408	FILE IPA
86	FILE NAPRALERT
573	FILE NLDB

QUE FIBRINOGEN

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, SCISEARCH, TOXCENTER, USPATFULL,
PASCAL, DRUGU, BIOTECHNO' ENTERED AT 12:25:57 ON 21 JAN 2005

L3 203636 S FIBRINOGEN
L4 473386 S MYOCARDIAL INFARCTION
L5 473386 S MYOCARDIAL (W) INFARCTION
L6 2525 S (MARKER OR (BIOMARKER)) AND L3 AND L5
L7 1897 DUP REM L6 (628 DUPLICATES REMOVED)
L8 670 S JACKOWSKI,G?/AU
L9 237 S THATCHER,B?/AU
L10 19338 S MARSHALL,J?/AU
L11 90 S YANTHA,J?/AU
L12 87 S VREES,T?/AU
L13 19980 S L8 OR L9 OR L10 OR L11 OR L12
L14 9671 DUP REM L13 (10309 DUPLICATES REMOVED)
L15 1889 S L7 NOT L14
L16 8 S L7 AND L14

=> d l16 ibib ti abs 1-8

L16 ANSWER 1 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
ACCESSION NUMBER: 2003:54591 BIOSIS
DOCUMENT NUMBER: PREV200300054591
TITLE: Post-translational modification of serum proteins underlies
the mass spectral fingerprinting of disease.
AUTHOR(S): **Marshall, John** [Reprint Author]; Kupchak, Peter
[Reprint Author]; Zhu, Weimin [Reprint Author];
Yantha, Jason [Reprint Author]; **Vrees,**
Tammy [Reprint Author]; Furesz, Shirley [Reprint
Author]; Jacks, Kelly [Reprint Author]; Smith, Chris
[Reprint Author]; Kireeva, Inga [Reprint Author]; Zhang,
Rulin [Reprint Author]; Takahashi, Miyoko [Reprint Author];
Stanton, Eric [Reprint Author]; **Jackowski, George**
[Reprint Author]
CORPORATE SOURCE: Synx Pharma, 1 Marmac Drive, Toronto, Ontario, M9W 1E7,
Canada
SOURCE: Molecular & Cellular Proteomics, (September 2002) Vol. 1,
No. 9, pp. 683. print.
Meeting Info.: First World Congress of the Human Proteome
Organisation. Versailles, Paris, France. November 21-24,
2002. Human Proteome Organisation.
ISSN: 1535-9476 (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 22 Jan 2003
Last Updated on STN: 22 Jan 2003
TI- Post-translational modification of serum proteins underlies the mass
spectral fingerprinting of disease.

L16 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:833556 CAPLUS
DOCUMENT NUMBER: 137:334916
TITLE: Alpha **fibrinogen** biopolymer **marker**
indicative of **myocardial infarction**
having a molecular weight of 1020 daltons
INVENTOR(S): **Jackowski, George; Thatcher, Brad;**
Marshall, John; Yantha, Jason;
Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161188	A1	20021031	US 2001-846350	20010430
US 6599877	B2	20030729		
WO 2002088728	A2	20021107	WO 2002-CA619	20020429
WO 2002088728	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846350 A 20010430

TI Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** having a molecular weight of 1020 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence DFLAEGGGVR and characterized as a α **fibrinogen** having a mol. weight of 1020 daltons was found. This **marker** is indicative of **myocardial infarction**.

L16 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:833425 CAPLUS

DOCUMENT NUMBER: 137:334901

TITLE: Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** or renal failure having a molecular weight of 1350 daltons

INVENTOR(S): **Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy**

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160528	A1	20021031	US 2001-845729	20010430
WO 2002088722	A2	20021107	WO 2002-CA610	20020426
WO 2002088722	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845729 A 20010430

TI Alpha **fibrinogen** biopolymer **marker** indicative of
myocardial infarction or renal failure having a
 molecular weight of 1350 daltons

AB The instant invention involves the use of a combination of preparatory
 steps in conjunction with mass spectroscopy and time-of-flight detection
 procedures to maximize the diversity of biopolymers which are verifiable
 within a particular sample. The cohort of biopolymers verified within
 such a sample is then viewed with reference to their ability to evidence at
 least one particular disease state; thereby enabling a diagnostician to
 gain the ability to characterize either the presence or absence of said at
 least one disease state relative to recognition of the presence and/or the
 absence of said biopolymer. Serum samples were analyzed by SELDI-TOF
 using the Ciphergen PROTEINCHIP system and the disease specific
marker identified by the sequence SESDFLAEGGGVR and characterized
 as a α **fibrinogen** having a mol. weight of 1350 daltons was
 found. This **marker** is indicative of **myocardial**
infarction or renal failure.

L16 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:833398 CAPLUS

DOCUMENT NUMBER: 137:334899

TITLE: Alpha **fibrinogen** biopolymer **marker**
 indicative of **myocardial infarction**
 having a molecular weight of 1536 daltons

INVENTOR(S): **Jackowski, George; Thatcher, Brad;**
Marshall, John; Yantha, Jason;
Vrees, Tammy

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160423	A1	20021031	US 2001-846780	20010430
WO 2002088718	A2	20021107	WO 2002-CA579	20020425
WO 2002088718	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846780 A 20010430

TI Alpha **fibrinogen** biopolymer **marker** indicative of
myocardial infarction having a molecular weight of 1536
 daltons

AB The instant invention involves the use of a combination of preparatory
 steps in conjunction with mass spectroscopy and time-of-flight detection

procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence ADSGEGDFLAEGGGVR and characterized as a α **fibrinogen** having a mol. weight of 1536 daltons was found. This **marker** is indicative of **myocardial infarction**.

L16 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:833397 CAPLUS

DOCUMENT NUMBER: 137:334898

TITLE: Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** having a molecular weight of 1077 daltons

INVENTOR(S): **Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy**

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160422	A1	20021031	US 2001-846342	20010430
WO 2002088708	A2	20021107	WO 2002-CA620	20020429
WO 2002088708	A3	20031023		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-846342 A 20010430

TI Alpha **fibrinogen** biopolymer **marker** indicative of **myocardial infarction** having a molecular weight of 1077 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence GDFLAEGGGVR and characterized as a α **fibrinogen** having a mol. weight of 1077 daltons was found. This **marker** is indicative of **myocardial infarction**.

L16 ANSWER 6 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2004:255419 USPATFULL

TITLE: Biopolymer **marker** indicative of disease state
having a molecular weight of 1518 daltons

INVENTOR(S): **Jackowski, George**, Kettleby, CANADA
Thatcher, Brad, Toronto, CANADA
Marshall, John, Toronto, CANADA
Yantha, Jason, Toronto, CANADA
Vrees, Tammy, Oakville, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004198950	A1	20041007
APPLICATION INFO.:	US 2001-845765	A1	20010430 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MCHALE & SLAVIN, P.A., 2855 PGA BLVD, PALM BEACH GARDENS, FL, 33410		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	696		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Biopolymer **marker** indicative of disease state having a
molecular weight of 1518 daltons

AB The instant invention involves the use of a combination of preparatory
steps in conjunction with mass spectroscopy and time-of-flight detection
procedures to maximize the diversity of biopolymers which are verifiable
within a particular sample. The cohort of biopolymers verified within
such a sample is then viewed with reference to their ability to evidence
at least one particular disease state; thereby enabling a diagnostician
to gain the ability to characterize either the presence or absence of
said at least one disease state relative to recognition of the presence
and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:4263 USPATFULL

TITLE: Biopolymer **marker** indicative of disease state
having a molecular weight of 1211 daltons

INVENTOR(S): **Jackowski, George**, Kettleby, CANADA
Thatcher, Brad, Toronto, CANADA
Marshall, John, Toronto, CANADA
Yantha, Jason, Toronto, CANADA
Vrees, Tammy, Oakville, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004307	A1	20030102
APPLICATION INFO.:	US 2001-845731	A1	20010430 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MCHALE & SLAVIN, 4440 PGA BLVD, SUITE 402, PALM BEACH GARDENS, FL, 33410		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	700		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Biopolymer **marker** indicative of disease state having a
molecular weight of 1211 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2002:301729 USPATFULL

TITLE: Biopolymer **marker** indicative of disease state
having a molecular weight of 1690 daltons

INVENTOR(S): **Jackowski, George**, Kettleby, CANADA
Thatcher, Brad, Toronto, CANADA
Marshall, John, Toronto, CANADA
Yantha, Jason, Toronto, CANADA
Vrees, Tammy, Oakville, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002169278	A1	20021114
	US 6593298	B2	20030715
APPLICATION INFO.:	US 2001-845730	A1	20010430 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MCHALE & SLAVIN, 4440 PGA BLVD, SUITE 402, PALM BEACH GARDENS, FL, 33410		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	699		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Biopolymer **marker** indicative of disease state having a molecular weight of 1690 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:22:08 ON 21 JAN 2005)

FILE 'REGISTRY' ENTERED AT 12:22:30 ON 21 JAN 2005

L1 1029 S FIBRINOGEN

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE,, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 12:23:04 ON 21 JAN 2005
SEA FIBRINOGEN

2029	FILE ADISCTI
138	FILE ADISINSIGHT
268	FILE ADISNEWS
502	FILE AGRICOLA
161	FILE ANABSTR
57	FILE ANTE
4	FILE AQUALINE
105	FILE AQUASCI
450	FILE BIOBUSINESS
118	FILE BIOCOMMERCE
515	FILE BIOENG
31334	FILE BIOSIS
576	FILE BIOTECHABS
576	FILE BIOTECHDS
6481	FILE BIOTECHNO
2010	FILE CABA
3587	FILE CANCERLIT
30223	FILE CAPLUS
115	FILE CEABA-VTB
5	FILE CEN
92	FILE CIN
695	FILE CONFSCI
11	FILE CROPU
1921	FILE DDFB
5797	FILE DDFU
5877	FILE DGENE
719	FILE DISSABS
1921	FILE DRUGB
99	FILE DRUGMONOG2
8235	FILE DRUGU
194	FILE EMBAL
34408	FILE EMBASE
5465	FILE ESBIODBASE
305	FILE FEDRIP
164	FILE FROSTI
134	FILE FSTA
4405	FILE GENBANK
44	FILE HEALSAFE
2002	FILE IFIPAT
48	FILE IMSDRUGNEWS
58	FILE IMSPRODUCT
61	FILE IMSRESEARCH
3834	FILE JICST-EPLUS
3	FILE KOSMET
2542	FILE LIFESCI
17	FILE MEDICONF
37491	FILE MEDLINE
164	FILE NIOSHTIC
354	FILE NTIS
4	FILE NUTRACEUT
15	FILE OCEAN
9706	FILE PASCAL
281	FILE PHAR
41	FILE PHARMAML
1	FILE PHIC
279	FILE PHIN
677	FILE PROMT
1752	FILE PROUSDDR
1	FILE PS
2	FILE RDISCLOSURE
22169	FILE SCISEARCH
17	FILE SYNTHLINE

```

12419  FILE TOXCENTER
11170  FILE USPATFULL
755    FILE USPAT2
27     FILE VETB
174    FILE VETU
3      FILE WATER
2425   FILE WPIDS
18     FILE WPIFV
2425   FILE WPINDEX
408    FILE IPA
86     FILE NAPRALERT
573    FILE NLDB
L2     QUE FIBRINOGEN
-----

```

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, SCISEARCH, TOXCENTER, USPATFULL, PASCAL, DRUGU, BIOTECHNO' ENTERED AT 12:25:57 ON 21 JAN 2005

```

L3      203636 S FIBRINOGEN
L4      473386 S MYOCARDIAL INFARCTION
L5      473386 S MYOCARDIAL (W) INFARCTION
L6      2525 S (MARKER OR (BIOMARKER)) AND L3 AND L5
L7      1897 DUP REM L6 (628 DUPLICATES REMOVED)
L8      670 S JACKOWSKI,G?/AU
L9      237 S THATCHER,B?/AU
L10     19338 S MARSHALL,J?/AU
L11     90 S YANTHA,J?/AU
L12     87 S VREES,T?/AU
L13     19980 S L8 OR L9 OR L10 OR L11 OR L12
L14     9671 DUP REM L13 (10309 DUPLICATES REMOVED)
L15     1889 S L7 NOT L14
L16     8 S L7 AND L14

```

=> s MALDI

```
L17      37915 MALDI
```

=> s L17 AND L7

```
L18      55 L17 AND L7
```

=> s L18 NOT L14

```
L19      52 L18 NOT L14
```

=> dup rem l19

PROCESSING COMPLETED FOR L19

```
L20      52 DUP REM L19 (0 DUPLICATES REMOVED)
```

=> d l20 ibib ti abs 40-52

L20 ANSWER 40 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:287670 USPATFULL

TITLE: Biopolymer **marker** indicative of disease state having a molecular of weight of 1525 daltons

INVENTOR(S): Jackowski, George, Kettleby, CANADA
 Thatcher, Brad, Toronto, CANADA
 Marshall, John, Toronto, CANADA
 Yantha, Jason, Toronto, CANADA
 Vrees, Tammy, Oakville, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160533	A1	20021031
APPLICATION INFO.:	US 2001-846779	A1	20010430 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: MCHALE & SLAVIN, 4440 PGA BLVD, SUITE 402, PALM BEACH
GARDENS, FL, 33410

NUMBER OF CLAIMS: 2

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 697

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Biopolymer **marker** indicative of disease state having a
molecular of weight of 1525 daltons

AB The instant invention involves the use of a combination of preparatory
steps in conjunction with mass spectroscopy and time-of-flight detection
procedures to maximize the diversity of biopolymers which are verifiable
within a particular sample. The cohort of biopolymers verified within
such a sample is then viewed with reference to their ability to evidence
at least one particular disease state; thereby enabling a diagnostician
to gain the ability to characterize either the presence or absence of
said at least one disease state relative to recognition of the presence
and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 41 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:287666 USPATFULL

TITLE: Biopolymer **marker** indicative of disease state
having a molecular weight of 1562 daltons

INVENTOR(S): Jackowski, George, Kettleby, CANADA
Thatcher, Brad, Toronto, CANADA
Vrees, Tammy, Oakville, CANADA
Yantha, Jason, Toronto, CANADA
Marshall, John, Toronto, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160529	A1	20021031
APPLICATION INFO.:	US 2001-845738	A1	20010430 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MCHALE & SLAVIN, 4440 PGA BLVD, SUITE 402, PALM BEACH GARDENS, FL, 33410		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	699		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Biopolymer **marker** indicative of disease state having a
molecular weight of 1562 daltons

AB The instant invention involves the use of a combination of preparatory
steps in conjunction with mass spectroscopy and time-of-flight detection
procedures to maximize the diversity of biopolymers which are verifiable
within a particular sample. The cohort of biopolymers verified within
such a sample is then viewed with reference to their ability to evidence
at least one particular disease state; thereby enabling a diagnostician
to gain the ability to characterize either the presence or absence of
said at least one disease state relative to recognition of the presence
and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 42 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:287571 USPATFULL

TITLE: Biopolymer **marker** indicative of disease state
having a molecular weight of 1777 daltons

INVENTOR(S): Jackowski, George, Kettleby, CANADA

Thatcher, Brad, Toronto, CANADA
Marshall, John, Toronto, CANADA
Yantha, Jason, Toronto, CANADA
Vrees, Tammy, Oakville, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160434	A1	20021031
APPLICATION INFO.:	US 2001-845735	A1	20010430 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MCHALE & SLAVIN, 4440 PGA BLVD, SUITE 402, PALM BEACH GARDENS, FL, 33410		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	700		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Biopolymer **marker** indicative of disease state having a molecular weight of 1777 daltons

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 43 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:206130 USPATFULL

TITLE: Methods and compositions for perioperative genomic profiling

INVENTOR(S): Hogan, Kirk, Madison, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110823	A1	20020815
APPLICATION INFO.:	US 2001-976423	A1	20011012 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-613887, filed on 11 Jul 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MEDLEN & CARROLL, LLP, 101 HOWARD STREET, SUITE 350, SAN FRANCISCO, CA, 94105		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	2232		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Methods and compositions for perioperative genomic profiling

AB The present invention relates to methods for perioperative genomic screening of subjects, in particular to perioperative screening for **markers** indicative of responses to anesthesia and other perioperative or operative treatments and procedures. The present invention also provides compositions for use in screening methods. The methods and compositions of the present invention find use in tailoring a subject's medical or surgical treatment to reflect genetic information that predicts a subject's response to medications or techniques used in the procedure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 44 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:191154 USPATFULL
TITLE: Diagnostic/therapeutic agents
INVENTOR(S): Klaveness, Jo, Oslo, NORWAY
Rongved, Pal, Oslo, NORWAY
Hogset, Anders, Oslo, NORWAY
Tolleshaug, Helge, Oslo, NORWAY
Cuthbertson, Alan, Oslo, NORWAY
Godal, Aslak, Oslo, NORWAY
Hoff, Lars, Oslo, NORWAY
Gogstad, Geir, Oslo, NORWAY
Bryn, Klaus, Oslo, NORWAY
Naevestad, Anne, Oslo, NORWAY
Lovhaug, Dagfinn, Oslo, NORWAY
Hellebust, Halldis, Oslo, NORWAY
Solbakken, Magne, Oslo, NORWAY
PATENT ASSIGNEE(S): Nycomed Imaging AS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102217	A1	20020801
	US 6680047	B2	20040120
APPLICATION INFO.:	US 2001-925715	A1	20010810 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-959206, filed on 28 Oct 1997, PATENTED		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22369	19961028
	GB 1997-2195	19970204
	GB 1997-8265	19970424
	GB 1997-11837	19970606
	GB 1997-11839	19970606
	US 1997-49263P	19970607 (60)
	US 1997-49264P	19970606 (60)
	US 1997-49266P	19970607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Richard E. Fichter, BACON & THOMAS, PLLC, Fourth Floor, 625 Slaters Lane, Alexandria, VA, 22314-1176	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	5190	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Diagnostic/therapeutic agents
AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 45 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:27111 USPATFULL
TITLE: Diagnostics and therapeutics for macular degeneration-related disorders
INVENTOR(S): Hageman, Gregory S., Coralville, IA, UNITED STATES

Mullins, Robert F., Coralville, IA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002015957	A1	20020207
APPLICATION INFO.:	US 2001-845745	A1	20010430 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-200698P	20000429 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	3111	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
TI	Diagnostics and therapeutics for macular degeneration-related disorders	
AB	The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 46 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:276121 USPATFULL

TITLE: Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response

INVENTOR(S): Romanczyk, Jr., Leo J., Hackettstown, NJ, United States
Schmitz, Harold H., Branchburg, NJ, United States

PATENT ASSIGNEE(S): Mars Incorporated, McLean, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6469053	B1	20021022
APPLICATION INFO.:	US 2000-507717		20000218 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-459171, filed on 10 Dec 1999 Continuation-in-part of Ser. No. US 1997-831245, filed on 2 Apr 1997, now patented, Pat. No. US 6297273 Continuation-in-part of Ser. No. US 1996-631661, filed on 2 Apr 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Solola, T. A.		
LEGAL REPRESENTATIVE:	Kelley, Margaret B., Chance, Clifford, Rogers & Wells		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	54 Drawing Figure(s); 48 Drawing Page(s)		
LINE COUNT:	2648		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
TI	Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response		
AB	Cocoa extracts which include procyanidin monomers and their oligomers are useful in the modulation of inflammatory pathways, in the maintenance of the vascular health of a mammal and as an antibacterial treatment. The liquid or dry cocoa extracts can be included in foods, food supplements and pharmaceuticals for the inhibition of COX activity, the inhibition of LOX activity, the enhancement of nitric oxide production, the modulation of eicosanoids and endothelin, and the modulation of platelet activity.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 47 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:254207 USPATFULL

TITLE: Treatment of a α -galactosidase a deficiency

INVENTOR(S): Selden, Richard F., Wellesley, MA, United States
Borowski, Marianne, Winthrop, MA, United States
Kinoshita, Carol M., Bedford, MA, United States
Treco, Douglas A., Arlington, MA, United States
Williams, Melanie D., Natick, MA, United States
Schuetz, Thomas J., Framingham, MA, United States
Daniel, Peter F., Natick, MA, United States
PATENT ASSIGNEE(S): Transkaryotic Therapies, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6458574	B1	20021001
APPLICATION INFO.:	US 1999-266014		19990311 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-928881, filed on 12 Sep 1996, now patented, Pat. No. US 6083725 Continuation-in-part of Ser. No. WO 1997-US16603, filed on 12 Sep 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-26041P	19960913 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Prouty, Rebecca E.	
ASSISTANT EXAMINER:	Hutson, Richard	
LEGAL REPRESENTATIVE:	Fish & Richardson PC	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 9 Drawing Page(s)	
LINE COUNT:	2880	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Treatment of a α -galactosidase a deficiency

AB The invention provides highly purified α -Gal A, and various methods for purifying it; α -Gal A preparations with altered charge and methods for making those preparations; α -Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making same; and methods and dosages for administering an α -Gal A preparation to a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 48 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:231041 USPATFULL

TITLE: Targeted diagnostic/therapeutic agents having more than one different vectors

INVENTOR(S): Klaveness, Jo, Olso, Norway
Rongved, P.ang.l, Olso, Norway
H.o slashed.gset, Anders, Olso, Norway
Tolleshaug, Helge, Olso, Norway
Cuthbertson, Alan, Olso, Norway
Hoff, Lars, Olso, Norway
Bryn, Klaus, Olso, Norway
Hellebust, Halldis, Olso, Norway
Solbakken, Magne, Olso, Norway
PATENT ASSIGNEE(S): Nycomed Imaging AS, Oslo, Norway (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 6331289	B1	20011218
APPLICATION INFO.:	US 1997-959206		19971028 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22369	19961028
	GB 1997-2195	19970204
	GB 1997-8265	19970424
	GB 1997-11837	19970606
	GB 1997-11839	19970606
	US 1997-49263P	19970606 (60)
	US 1997-49266P	19970607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 4091

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Targeted diagnostic/therapeutic agents having more than one different vectors
AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 49 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:231038 USPATFULL
TITLE: Structurally determined cyclic metallo-constructs and applications
INVENTOR(S): Sharma, Shubh D., Plainsboro, NJ, United States
PATENT ASSIGNEE(S): Palatin Technologies, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6331285	B1	20011218
APPLICATION INFO.:	US 1999-464358		19991215 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-660697, filed on 5 Jun 1996, now patented, Pat. No. US 6027711		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Jones, Dameron L.		
LEGAL REPRESENTATIVE:	Slusher, Stephen A. Peacock, Myers & Adams		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	4839		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Structurally determined cyclic metallo-constructs and applications
AB A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 50 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2000:21206 USPATFULL

TITLE: Structurally determined metallo-constructs and applications

INVENTOR(S): Sharma, Shubh D., Albuquerque, NM, United States

PATENT ASSIGNEE(S): RhoMed Incorporated, Edison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6027711		20000222
APPLICATION INFO.:	US 1996-660697		19960605 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-476652, filed on 7 Jun 1995, now patented, Pat. No. US 5891418, issued on 6 Apr 1999		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Jones, Dameron		
LEGAL REPRESENTATIVE:	Slusher, Stephen A., Todaro, John C., Peacock, Deborah A.		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	4915		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Structurally determined metallo-constructs and applications

AB A metallo-construct, which may be a peptide, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a metal ion. The peptide constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing metal ions, so that substantially all of the valences of the metal ion are satisfied upon complexation of the metal ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the metal ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance

of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a ligand or mimic a known biological-function domain. The construct has substantially higher affinity for its target upon labeling with a metal ion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 51 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1998:42387 USPATFULL

TITLE: Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors

INVENTOR(S): Illig, Carl R., Phoenixville, PA, United States
Soll, Richard M., Lawrenceville, NJ, United States
Salvino, Joseph M., Schwenksville, PA, United States
Tomczuk, Bruce E., Collegeville, PA, United States
Lu, Tianbao, Exton, PA, United States

PATENT ASSIGNEE(S): Subasinghe, Nalin L., West Chester, PA, United States
3-Dimensional Pharmaceuticals, Inc., Exton, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5741819		19980421
APPLICATION INFO.:	US 1995-488196		19950607 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Owens, Amelia		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox, P.L.L.C.		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1240		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors

AB The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds of structure: ##STR1## or pharmaceutically acceptable salts thereof; wherein

R.sup.1 is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; R.sup.2 is one of hydrogen, alkyl, cycloalkyl or aryl; R.sup.3 is one of hydrogen, hydroxy or alkoxy; R.sup.4 is one of --NH.sub.2, phenyl or pyridyl, wherein said phenyl and said pyridyl are optionally substituted with one or two of halogen, hydroxy, hydroxyalkyl, alkoxy, amino, monoalkylamino, dialkylamino, aminoalkyl, monoalkylaminoalkyl and/or dialkylaminoalkyl; X is one of --CH.sub.2 -- or --C(O)--; and n is from zero to eleven; provided that when R.sup.4 is --NH.sub.2, then R.sup.3 is hydrogen and n is other than zero; and also provided that when R.sup.3 is hydroxy or alkoxy, then R.sup.4 is other than --NH.sub.2, and n is other than zero.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 52 OF 52 USPATFULL on STN

ACCESSION NUMBER: 97:22821 USPATFULL

TITLE: Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors

INVENTOR(S): Tianbao, Lu, Exton, PA, United States
Soll, Richard M., Lawrenceville, NJ, United States

PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., Exton, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5612378		19970318
APPLICATION INFO.:	US 1995-470579		19950606 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jos e G.		
ASSISTANT EXAMINER:	Ledynh, Lily		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	730		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors

AB The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds of structure: ##STR1## wherein each R.sup.1 is independently one of alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;

each R.sup.2 and R.sup.3 is independently one of hydrogen, alkyl, aryl or arylalkyl;

Y is a bond, or is one of --(CH.sub.2).sub.p --, cycloalkyl, aryl or C.sub.2-10 heterocycle; and

m, n and p are each independently 1 to 10.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> DIS HIST

(FILE 'HOME' ENTERED AT 12:22:08 ON 21 JAN 2005)

FILE 'REGISTRY' ENTERED AT 12:22:30 ON 21 JAN 2005

L1 1029 S FIBRINOGEN

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 12:23:04 ON 21 JAN 2005
SEA FIBRINOGEN

2029 FILE ADISCTI
138 FILE ADISINSIGHT
268 FILE ADISNEWS
502 FILE AGRICOLA
161 FILE ANABSTR
57 FILE ANTE
4 FILE AQUALINE
105 FILE AQUASCI
450 FILE BIOBUSINESS
118 FILE BIOCOMMERCE
515 FILE BIOENG
31334 FILE BIOSIS
576 FILE BIOTECHABS
576 FILE BIOTECHDS
6481 FILE BIOTECHNO

2010	FILE CABA
3587	FILE CANCERLIT
30223	FILE CAPLUS
115	FILE CEABA-VTB
5	FILE CEN
92	FILE CIN
695	FILE CONFSCI
11	FILE CROPU
1921	FILE DDFB
5797	FILE DDFU
5877	FILE DGENE
719	FILE DISSABS
1921	FILE DRUGB
99	FILE DRUGMONOG2
8235	FILE DRUGU
194	FILE EMBAL
34408	FILE EMBASE
5465	FILE ESBIODBASE
305	FILE FEDRIP
164	FILE FROSTI
134	FILE FSTA
4405	FILE GENBANK
44	FILE HEALSAFE
2002	FILE IFIPAT
48	FILE IMSDRUGNEWS
58	FILE IMSPRODUCT
61	FILE IMSRESEARCH
3834	FILE JICST-EPLUS
3	FILE KOSMET
2542	FILE LIFESCI
17	FILE MEDICONF
37491	FILE MEDLINE
164	FILE NIOSHTIC
354	FILE NTIS
4	FILE NUTRACEUT
15	FILE OCEAN
9706	FILE PASCAL
281	FILE PHAR
41	FILE PHARMAML
1	FILE PHIC
279	FILE PHIN
677	FILE PROMT
1752	FILE PROUSDDR
1	FILE PS
2	FILE RDISCLOSURE
22169	FILE SCISEARCH
17	FILE SYNTHLINE
12419	FILE TOXCENTER
11170	FILE USPATFULL
755	FILE USPAT2
27	FILE VETB
174	FILE VETU
3	FILE WATER
2425	FILE WPIDS
18	FILE WPIFV
2425	FILE WPINDEX
408	FILE IPA
86	FILE NAPRALERT
573	FILE NLDB
	QUE FIBRINOGEN

L2

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, SCISEARCH, TOXCENTER, USPATFULL,

PASCAL, DRUGU, BIOTECHNO' ENTERED AT 12:25:57 ON 21 JAN 2005

L3 203636 S FIBRINOGEN
L4 473386 S MYOCARDIAL INFARCTION
L5 473386 S MYOCARDIAL (W) INFARCTION
L6 2525 S (MARKER OR (BIOMARKER)) AND L3 AND L5
L7 1897 DUP REM L6 (628 DUPLICATES REMOVED)
L8 670 S JACKOWSKI,G?/AU
L9 237 S THATCHER,B?/AU
L10 19338 S MARSHALL,J?/AU
L11 90 S YANTHA,J?/AU
L12 87 S VREES,T?/AU
L13 19980 S L8 OR L9 OR L10 OR L11 OR L12
L14 9671 DUP REM L13 (10309 DUPLICATES REMOVED)
L15 1889 S L7 NOT L14
L16 8 S L7 AND L14
L17 37915 S MALDI
L18 55 S L17 AND L7
L19 52 S L18 NOT L14
L20 52 DUP REM L19 (0 DUPLICATES REMOVED)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	103.52	111.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.92	-2.92

STN INTERNATIONAL LOGOFF AT 12:45:08 ON 21 JAN 2005